

FORM PTO-1449 (Rev. 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 31927	SERIAL NO.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT: MESSADEK, Jallal	
(Use several sheets if necessary)		FILING DATE:	GROUP:
		1050 U.S. PRO 09/94 5391 08/31/01	

U.S. PATENT DOCUMENTS

EXAM. INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
CPO	A	9	7	0	6	7	9	5	21.08.96	WO			YES	NO
	B	6	7	8	1	5	5	4	23.07.96	EPO				
	C	9	8	1	8	6	9	0	06.11.96	WO				
	D	9	5	1	5	7	5	0	10.12.93	WO				
	R	9	7	3	8	6	8	5	12.04.96	WO				
	F	0	3	4	7	8	6	4	20.06.89	EPO				
CPO	G	0	0	2	5	7	6	4	30.10.98	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CPO	H	*	Article from Entrez-PubMed web page entitled: SR 121787, a new orally active fibrinogen receptor antagonist.
	I	*	Article from Entrez-PubMed web page entitled: Antiaggregatory, antithrombotic effects of MS-180, a novel platelet glycoprotein IIb/IIIa receptor antagonist.
	J	*	Article from Entrez-PubMed web page entitled: Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
	K	*	Article from Entrez-PubMed web page entitled: SR 121787, Prevention of thrombosis and enhancement of thrombolysis in rabbits by SR 121787, a glycoprotein II/III antagonist.
	L	*	Article from Entrez-PubMed web page entitled: Role of platelets in thrombosis and hemostasis.
	M	*	Article from Entrez-PubMed web page entitled: Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383.
	N	*	Article from Entrez-PubMed web page entitled: The in vitro and in vivo pharmacological profiles of a platelet glycoprotein IIb/IIIa antagonist, NSL-9403.
CPO	O	*	Article from Entrez-PubMed web page entitled: antiplatelet and antithrombotic effects of orbofiban, a new orally active GPIIb/IIIa antagonist, in guinea pigs.

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* Abstract Only!

FORM PTO-1449 (Rev. 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 31927	SERIAL NO. 09/945,391
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT: MESSADEK, Jallal	
(Use several sheets if necessary)		FILING DATE: August 31, 2001	GROUP: 1614

U.S. PATENT DOCUMENTS

EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
CTO	P	* HU 210,122 B	✓	9/28/1992	HU		YES <input checked="" type="checkbox"/> NO <input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CTO	Q	✓	XP-002123170 Database Chemabs 'Online!'; Chemical Abstracts Service, Columbus, OH ZAPADNYUK, B.I. et al.: "Bile-secretory effect of trimethylglycine in normal and atherosclerotic animals of different ages" retrieved from STN Database accession no. 107:190742 HCA abstract & BYULL. EKSP. BIOL. MED. (1987), 104(7), 30-2
	R	✓	XP002123171 Database Chemabs 'Online!'; Chemical ABstracts Service, Columbus, OH PANTELEIMONOVA, T.N. et al.: "Effect of trimethylglycine on lipid metabolism in rabbits with experimental atherosclerosis" retrieved from STN Database accession no. 99:99080 HCA abstract & FARMAKOL. TOKSIKOL. (MOSCOW) (1983), 46(4), 83-5
	S	*	XP-000853747 Fazio B Et al: "Treatment of human atherosclerosis with betaine." MINERVA MED, (1961 APR 25) 52 1511-6., the whole document
	T	*	XP-002123167 P.H. List et al.: "HAGERS HANDBUCH DER PHARMAZEUTISCHEN PRAXIS" 1972, SPRINGER-VERLAG, BERLIN HEIDELBERG, NEW YORK, page 431
	U	✓	XP000853853 "Betaine for homocystinuria." MEDICAL LETTER ON DRUGS AND THERAPEUTICS, (1997) 39/993 (12), the whole document
	V	✓	XP000853897 WILCKEN D E ET AL: "The natural history of vascular disease in homocystinuria and the effects of treatment." JOURNAL OF INHERITED METABOLIC DISEASE, (1997 JUN) 20 (2) 295-300., the whole document
	W	✓	XP-002123168 J.E.F. REYNOLDS: "MARTINDALE, The Extra Pharmacopoeia" 1996, ROYAL PHARMACEUTICAL SOCIETY, LONDON "Betaine hydrochloride" page 1679
CTO	X	✓	XP002123169 "the merck index" 1996, MERCK & CO, WHITHOUSE STATIONS, NJ "Betaine" page 198

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* not in English
✓ Abstract Only